+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Kuwait Pharmaceuticals Market Outlook to 2022 - By Type of Drugs; By Channel of Distribution and By Therapeutic Class

  • ID: 4769096
  • Report
  • November 2018
  • Region: Kuwait
  • 103 Pages
  • Ken Research Private Limited
1 of 3

FEATURED COMPANIES

  • Abbott
  • Al- Hajery
  • AstraZeneca
  • Hikma Pharmaceuticals
  • Julphar
  • Novartis
  • MORE

The report titled “Kuwait Pharmaceuticals Market Outlook to 2022 - By Type of Drugs (Generic and Patented Drugs); By Channel of Distribution (Institutional Sales and Retail Sales) and By Therapeutic Class (Anti-Infectives, Gastrointestinal, Cardiovascular, CNS, Respiratory, Musculoskeletal, Analgesics and Anti Inflammatory and Others)” provides a comprehensive analysis on introduction on Kuwait Pharmaceuticals market, value chain, stakeholders in Kuwait pharmaceuticals market ecosystem, market size by revenue (2012-2017), overall pharmaceuticals market segmentation by type of drug, by OTC and prescription drugs, by end users, by channel of distribution and by therapeutic class, competition scenario in the industry, shares and company profiles of major players in the market, growth drivers, trends and developments, issues and challenges in the pharmaceuticals market and the regulatory framework of the industry. The report also includes future outlook for the market (2018-2022) including estimated market size in terms of revenue and pharmaceuticals market segmentation by therapeutic class.

The report is useful for manufacturers, distributors, retailers of pharmaceuticals, hospital chains, Drug stockiest, Healthcare IT companies to align their market centric strategies according to ongoing and expected trends in the future.

Kuwait Pharmaceuticals Market Overview
The Kuwait Pharmaceuticals market is in the growing stage and is primarily driven by government’s healthcare initiatives. A booming oil and gas industry and limited diversification into other sectors have significantly constrained the manufacturing activities in Kuwait. As a result, domestic production of medicines in the country continued to be low and majority of the pharmaceuticals consumed were imported in this period, including branded and generic drugs. Although the industry is closely monitored by the government, medicine prices in Kuwait continued to be high. Doctors and patients generally prefer patented and branded products, which has stretched the government funding system. Prevalence of chronic disorders such as cardiovascular, diabetes, cancer and respiratory conditions was also on a rise which gave a boost to the demand for pharmaceuticals market.

The trend towards preventive healthcare witnessed a rise in line with an increase in healthcare awareness in this period, thus supporting expansion of the OTC segment and increasing demand for OTC medication and pseudo-pharmaceuticals such as vitamins and supplements, weight loss formulations, and smoking cessation aids. High public spending on healthcare and a free of cost provision of medical services for the locals have supported demand for pharmaceuticals in the country in this period. A number of government initiatives are also driving the pharmaceuticals market in Kuwait such granting 12 companies medical permits to build pharmaceutical factories in collaboration with the Public Authority for Industry (PAI) in the country, almost doubling the budget for healthcare spending between 2010 and 2016, reaching close to KD 2 billion (USD 6.6 Billion) in 2016 and more than 20 large governmental healthcare projects in the pipeline worth KD 3.5 billion (USD 12 billion) in the country.

Market Segmentation:
In 2017, patented drugs dominated the Pharmaceuticals market of Kuwait as compared to generic drugs in terms of revenue. This is because branded and patented drugs are more popular in the country due to the relative wealth of the population and expatriate workers. The high price of patented drugs when compared to generic drugs has also resulted in the higher market share of patented drugs in terms of revenue share in the market. Prescription drugs sales had a major revenue share in Kuwait Pharmaceuticals Market while OTC drugs had a smaller share. The demand for prescription drugs is driven by the increased number of patients at hospitals and clinics who mainly prefer prescribed drugs. The growth in spending can be attributed to new brands, high prices for existing drugs and fewer patent expiries. In 2017, Institutional sales have accounted for a much larger revenue share as compared to retail sales. Analgesics and Anti Inflammatory drugs had the largest market share in the Pharmaceuticals market in Kuwait in terms of revenue. This is because of the wide range of applications such as treatment of fever, headaches, flu, colds, musculoskeletal injuries and disorders, arthritis, toothaches, and menstrual cramps increases the revenue share of this segment. This was followed by respiratory, cardiovascular, gastrointestinal, anti infectives, CNS and musculoskeletal.

Competitive Landscape
The Kuwait Pharmaceuticals market is highly fragmented. It is dominated by foreign corporations in Kuwait and the only indigenous manufacturer of Kuwait operating in the pharmaceuticals market is Kuwait Saudi Pharmaceutical Industries Company (KSPICO). The regional/local players of the Middle East operating in Kuwait comprised of companies such as Julpar, Spimaco, Tabuk, Hikma Pharmaceuticals etc. In 2017, Pfizer had the highest market share in the Pharmaceuticals market in Kuwait followed by AstraZeneca, Abbvie, Novartis, GSK, Roche, MSD, Sanofi, Johnson & Johnson, Abbott, Julphar, Tabuk and Hikma Pharmaceuticals on the basis of revenue.

Future Outlook
The future outlook of the industry is positive and the industry growth will be led by the widespread prevalence of chronic diseases, growing population and the high per capita income of the people in the country. The limited indigenous manufacturing capabilities also present a number of growth opportunities for multinational and regional pharmaceutical companies to enter the Kuwait pharmaceuticals industry. The large investments which have been undertaken for development of the healthcare sector through the public-private partnership (PPP) route is expected to grow the pharmaceuticals market too in the coming years. The availability of generic products is anticipated to increase as private health insurance schemes are encouraging prescribers to adopt more rational prescription patterns. As Kuwait accelerates its healthcare development strategy as part of the Kuwait Vision 2035, both Kuwait's pharmaceutical and healthcare markets have been noted as high-priority sectors, with many projects set to be carried out under public-private partnerships (PPPs). Furthermore, chronic diseases such as cardiovascular, diabetes, obesity, cancer and respiratory conditions are rising dramatically in Kuwait primarily due to less physical activity and dietary habits such as increased fast food consumption linked to high-income generation. Thus the market shares of anti-infective, gastrointestinal, cardiovascular and musculoskeletal are expected to increase in the Kuwait pharmaceuticals market by 2022.

Key Segments Covered

By Type of Drug

  • Generic Drugs
  • Patented Drugs

By OTC and Prescription Drugs

  • OTC Drugs
  • Prescription Drugs

By End Users

  • Public Sector
  • Private Sector

By Channel of Distribution

  • Institutional Sales
  • Retail Sales

By Therapeutic Class

  • Anti-Infectives
  • Gastrointestinal
  • Cardiovascular
  • CNS
  • Respiratory
  • Musculoskeletal
  • Analgesics and Anti Inflammatory
  • Others

Companies Covered:

  • Pharmaceutical Companies: Pfizer, AstraZeneca, Abbvie, Novartis, GSK, Roche, MSD, Sanofi, Johnson & Johnson, Abbott, Julphar, Tabuk, Hikma Pharmaceuticals, Kuwait Saudi Pharmaceutical Industries Company (KSPICO),
  • Distributors: Al Mojil Drug Company, YIACO Medical Company, Bader Sultan And Brothers Company, Ali Abdulwahab Al Mutawa Commercial Company, Pharmazone and Al- Hajery

Key Topics Covered in the Report

  • Introduction on Kuwait Pharmaceuticals Market
  • Value Chain
  • Stakeholders in Kuwait Pharmaceuticals Market Ecosystem
  • Market Size by Revenue (2012-2017)
  • Pharmaceuticals Market Segmentation by Type of Drug, by OTC And Prescription Drugs, by End Users, by Channel of Distribution and by Therapeutic Class
  • Competition Scenario in the Industry
  • Shares and Company Profiles of Major Players in the Market
  • Growth Drivers, Trends and Developments in the Pharmaceuticals Market
  • Issues and Challenges in the Pharmaceuticals Market
  • Regulatory Framework of the Industry
  • Future Outlook for the Market (2018-2022) Including Estimated Market Size in Terms of Revenue and Pharmaceuticals Market Segmentation by Therapeutic Class
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott
  • Al- Hajery
  • AstraZeneca
  • Hikma Pharmaceuticals
  • Julphar
  • Novartis
  • MORE

1. Executive Summary
1.1 Market Overview
1.2 Market Size
1.3 Market Segmentation
1.4 Competitive Landscape
1.5 Growth Drivers, Issues and Challenges
1.6 Future Analysis and Projections

2. Research Methodology
2.1. Market Definitions
2.2. Abbreviation
2.3. Market Size and Modeling
2.3.1 Research Methodology
2.3.2 Market Sizing
2.3.3 Limitation
2.3.4 Variables (Dependent and Independent)
2.3.5 Multifactor Based Sensitivity Model
2.3.6 Final Conclusion

3. Kuwait Pharmaceuticals Market Overview
3.1. Kuwait Pharmaceuticals Market Overview
3.2. Value Chain
3.3. Stakeholders in Kuwait Pharmaceuticals Market Ecosystem

4. Kuwait Pharmaceuticals Market Size, 2012-2017

5. Kuwait Pharmaceuticals Market Segmentation, 2017
5.1. By Type of Drug, 2017
5.2. By OTC and Prescription Drugs, 2017
5.3. By End Users, 2017
5.4. By Channel of Distribution, 2017
5.5. By Therapeutic Class, 2017

6. Growth Drivers, Trends and Developments in Kuwait Pharmaceuticals Market
6.1. Growing Population
6.2. Increasing Use of Generic Drugs
6.3. Widespread Prevalence of Non- Communicable and Chronic Diseases
6.4. FDI in Kuwait

7. Issues and Challenges in Kuwait Pharmaceuticals Market
7.1. High Dependence on Imports
7.2. High Prices of Pharmaceutical Products
7.3. Ineffective Legal Protection for Pharmaceutical Product Patents

8. Regulatory framework in Kuwait Pharmaceuticals Market
8.1. GCC Central Drug Registration (GCC-DR) Committee
8.2. Drug Registration Requirements in Kuwait Pharmaceuticals Market
8.3. Regulatory Process of Kuwait
8.3.1. The Submission Phase
8.3.2. The Evaluation Phase
8.3.3. The Authorization Phase
8.4. Data Requirements in Kuwait Pharmaceutical Market
8.4.1. Information Required
8.4.2. Certificates Required

9. Competition Scenario
9.1. Company Profiles of Major Manufacturers in Kuwait Pharmaceutical Market
9.1.1. Kuwait Saudi Pharmaceutical Industries Company
9.1.2. Pfizer
9.1.3. AstraZeneca
9.1.4. AbbVie
9.1.5. Novartis
9.2. Company Profiles of Major Distributors in Kuwait Pharmaceutical Market
9.2.1. Al Mojil Drug Company K.S.C.C.
9.2.2. YIACO Medical Company
9.2.3. Bader Sultan and Brothers Company WLL (BSBC)
9.2.4. Ali Abdulwahab Al Mutawa Commercial Company K.S.C.C. (AAW)
9.2.5. Pharmazone
9.2.6. Al- Hajery

10. Kuwait Pharmaceutical Market Future Outlook and Projections, 2018-2022
10.1. Kuwait Pharmaceuticals Future Segmentation by Therapeutic Class, 2022

11. Analyst Recommendations

12. Macroeconomic Factors in Kuwait Pharmaceuticals Market, 2012-2022E
12.1. Number of Inpatients, 2012-2022E
12.2. Number of Operations Performed, 2012-2022E
12.3. Number of Outpatients, 2012-2022E

List of Figures
Figure 1 1: Executive Summary of Kuwait Pharmaceuticals Market at Distributors’ Level
Figure 3 1: Value Chain Analysis of Kuwait Pharmaceuticals Market
Figure 4 1: Kuwait Pharmaceutical Market Size on the Basis of Revenue in USD Million and Growth Rate in Percentage (%), 2012-2017
Figure 5 1: Kuwait Pharmaceuticals Market Segmentation by Type of Drug (Patented and Generic Drug) on the basis of Revenues in Percentage (%), 2017
Figure 5 2: Kuwait Pharmaceuticals Market Segmentation by OTC and Prescription Drugs on the basis of Revenues in Percentage (%), 2017
Figure 5 3: Kuwait Pharmaceuticals Market Segmentation by End Users (Public Sector and Private Sector) on the basis of Revenues in Percentage (%), 2017
Figure 5 4: Kuwait Pharmaceuticals Market Segmentation by Channel of Distribution (Institutional Sales and Retail Sales) on the basis of Revenues in Percentage (%), 2017
Figure 5 5: Kuwait Pharmaceuticals Market Segmentation by Therapeutic Class (Anti-Infectives, Gastrointestinal, Cardiovascular, CNS, Respiratory, Musculoskeletal, Analgesics and Anti Inflammatory and Others) on the basis of Revenues in Percentage (%), 2017
Figure 8 1: Regulatory Process of Kuwait Pharmaceuticals Industry
Figure 9 1: Market Share of Major Players in Kuwait Pharmaceuticals Market on the Basis of Revenues in Percentage (%), 2017
Figure 9 2: Revenue from Pharmaceutical Sales of YIACO Medical Company in KD Million, 2012-17
Figure 10 1: Kuwait Pharmaceutical Market Future Projections on the Basis of Revenue in USD Million and Growth Rate in Percentage (%), 2017-2022
Figure 10 2: Kuwait Pharmaceuticals Future Market Segmentation by Therapeutic Class (Anti-Infectives, Gastrointestinal, Cardiovascular, CNS, Respiratory, Musculoskeletal, Analgesics and Anti Inflammatory and Others) on the basis of Revenues in Percentage (%), 2022E
Figure 12 1: Number of Inpatients in Kuwait, 2012-2022E
Figure 12 2: Number of Operations Performed in Kuwait, 2012-2022E
Figure 12 3: Number of Outpatients in Kuwait, 2012-2022E
 
List of Tables
Table 2 1: Therapeutic Segments Covered in Kuwait Pharmaceutical Market
Table 2 2: Correlation Matrix of Kuwait Pharmaceuticals Market
Table 2 3: Regression Coefficient Output for Kuwait Pharmaceuticals Market
Table 3 1: Introduction to Kuwait Pharmaceutical Industry
Table 3 2: Value Chain Analysis of Kuwait Pharmaceuticals Market
Table 3 3: Kuwait Pharmaceuticals Market Ecosystem
Table 4 1: Key Developments in Kuwait Pharmaceutical Market, 2012-2017
Table 5 1: Rationale and Description for Kuwait Pharmaceuticals Market Segmentation by Type of Drug (Patented and Generic) on the Basis of Revenue, 2017
Table 5 2: Key Rationale and Description for Kuwait Pharmaceuticals Market Segmentation by OTC and Prescription Drugs in Terms of Revenue, 2017
Table 5 3: Key Rationale and Description for Kuwait Pharmaceuticals Market Segmentation by End Users (Public and Private Sector) in Terms of Revenue, 2017
Table 5 4: Number of Hospitals (Public Sector, Private Sector & Oil Companies) in Kuwait, 2013-2017
Table 5 5: Key Rationale and Description for Kuwait Pharmaceuticals Market Segmentation by Channel of Distribution Including Institutional Sales and Retail Sales in Terms of Revenue in USD Million, 2017
Table 5 6: Key Rationale and Description for Kuwait Pharmaceuticals Market Segmentation by Therapeutic Class Including Anti-Infectives, Gastrointestinal, Cardiovascular, CNS, Respiratory, Musculoskeletal, Analgesics and Anti Inflammatory and Others on the Basis of Revenue, 2017
Table 5 7: New Product Launches for Various Therapeutic Classes including Alimentary, Cardio, Anti- Inflammatory SY, Anti- Neoplasm, Nervous, Respiratory, Derma, Genitourinary System, Blood and Musculoskeletal in MAT Q1, 2018
Table 5 8: Kuwait Top Ten Causes of Deaths in 2016 and Percentage Change 2005-2016
Table 6 1: FDI in Kuwait, 2015-2017
Table 9 1: Competition Scenario in Kuwait Pharmaceuticals Market Including Competition Stage, Company Position and Parameters of Competition
Table 9 2: Competitive Parameters in Kuwait Pharmaceutical Market
Table 9 3: Strengths of Major Players in Kuwait Pharmaceutical Market, 2017
Table 9 4: Fastest Growing Companies among the Top 30 Companies in Kuwait Pharmaceuticals Market by Value Sales Including Previous Period Growth
Table 9 5: Top Selling Products of Major Players in Kuwait Pharmaceuticals Market Including Product Sales in USD Million in MAT Q1 2018
Table 9 6: Market Share of Major Players in Kuwait Pharmaceuticals Market on the Basis of Revenues in USD Million, 2017
Table 9 7: Company Profile of Kuwait Saudi Pharmaceutical Industries Company (KSPICO) including Company Overview, Product Lines, Facilities, Production Capacity, Future Prospective, Major Suppliers, Partner Distributors and Major Clients
Table 9 8: Product Portfolio of Kuwait Saudi Pharmaceutical Industries Company (KSPICO)
Table 9 9: Company Profile of Pfizer including Company Overview, Business Segments, Distributors, Revenue, USP and Recent Developments, 2017
Table 9 10: Company Profile of AstraZeneca including Company Overview, Business Segments, Distributors, Revenue, USP and Recent Developments, 2017
Table 9 11: Company Profile of AbbVie including Company Overview, Business Segments, Distributors, Revenue, USP and Recent Developments, 2017
Table 9 12: Company Profile of AbbVie including Company Overview, Business Segments, Distributors, Revenue, USP and Recent Developments, 2017
Table 9 13: Company Profile of Al Mojil Drug Company including Company Overview, Business Segments, Pharmaceutical Suppliers, Awards and Certificates and Future Plans
Table 9 14: Company Profile of YIACO Medical Company including Company Overview, Divisions, Number of Employees, Services Offered, Operating Model, Business Strategies, Strengths and Recent Developments
Table 9 15: Company Profile of Bader Sultan And Brothers Company WLL including Company Overview, Divisions, Pharmaceuticals Suppliers, Location, Strengths and Recent Developments
Table 9 16: Company Profile of Ali Abdulwahab Al Mutawa Commercial Company (AAW) including Company Overview, Business Lines, Pharmaceutical Subsidiary Companies, Operating Model, Business Strategy, Marketing Strategy, Strengths and Recent Developments
Table 9 17: Company Profile of Pharmazone Including Company Overview, Strengths, Product Range Offered, Operating Models, Business Strategies, Marketing Strategies, Major Supplier of brands and Recent Development
Table 9 18: Company Profile of Al- Hajery Pharmacy Including Company Overview, Sister Companies, Operating Model, Strengths, Business Strategies and Major Supplier of the Brands
Table 10 1: Rationale and Description for Future Projections in Kuwait Pharmaceutical Market, 2018-2022
Table 10 2: Upcoming Private Sector Hospital Projects in Kuwait
Table 10 3: Upcoming Public Sector Hospitals Project in Kuwait
Table 10 4: Kuwait Hospital Market Upcoming Project
Table 10 5: Key Takeaways for Future Projection of Kuwait Pharmaceuticals Market Segmentation by Therapeutic Class (Anti-Infectives, Gastrointestinal, Cardiovascular, CNS, Respiratory, Musculoskeletal, Analgesics and Anti Inflammatory and Others) on the basis of Revenues in USD Million, 2022E
Table 11 1: Analyst Recommendations for Kuwait Pharmaceuticals Market
Table 12 1: Key Developments in Number of Inpatients in Kuwait, 2012-2022E
Table 12 2: Key Developments in Number of Operations Performed in Kuwait, 2012-2022E
Table 12 3: Key Developments in Number of Outpatients in Kuwait, 2012-2022E

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbott
  • Abbvie
  • Al Mojil Drug Company
  • Al- Hajery
  • Ali Abdulwahab Al Mutawa Commercial Company
  • AstraZeneca
  • Bader Sultan And Brothers Company
  • GSK
  • Hikma Pharmaceuticals
  • Johnson & Johnson
  • Julphar
  • Kuwait Saudi Pharmaceutical Industries Company (KSPICO)
  • MSD
  • Novartis
  • Pfizer
  • Pharmazone
  • Roche
  • Sanofi
  • Tabuk
  • YIACO Medical Company
Note: Product cover images may vary from those shown
Adroll
adroll